Gain Therapeutics, Inc. filed 1 current report with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-09-28. Between them they name 1 person. Each change below is quoted from the filing and linked to it.
Every change, newest first
Appointed: Gene Mack, Chief Financial Officer, effective 2026-10-01
On September 24, 2026, the Company's board of directors appointed Gene Mack, the Company's current President and Chief Executive Officer, to serve as the Company's interim Chief Financial Officer, effective as of October 1, 2026.
Find people with the same kind of experience as the Chief Financial Officer at Gain Therapeutics, Inc., with the record behind each one.
Find candidates like Chief Financial Officer at Gain Therapeutics, Inc.New leaders review vendors and budgets in their first months. Get an alert the next time Gain Therapeutics, Inc. is in the news or changes leadership.
Get an alert when Gain Therapeutics, Inc. changes leadershipWant the whole picture on Gain Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Gain Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Gain Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Tools for this story
Each opens in a new tab, filled in for Gain Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.